



Summary of congress activities

Cardiovascular inflammation in cardiovascular disease

Novo Nordisk at the 76th European Society of
Cardiology (ESC) Congress, Munich, Germany
28–31 August 2026



Disclaimer

The summary is provided as part of Novo Nordisk's commitment to enhance the educational content and learning experience to support scientific exchange with the medical community.

The summary is not meant to guide treatment decisions, and it does not make any claim(s) for any medicine. For the indications and proper use of Novo Nordisk products, refer to the product's approved label for your country.

Cardiovascular inflammation in cardiovascular disease

Novo Nordisk at ESC Congress 2026

POSEIDON: CV inflammation is highly prevalent in patients with **HF**, and in those with ASCVD and CKD^{1,2}

~2/5
patients have
hsCRP ≥ 2 mg/L

hsCRP is a biomarker of CV inflammation and levels ≥ 2 mg/L are associated with **increased CV risk** across CVD populations³⁻⁸

Universal screening of hsCRP can provide **prognostic information on CV risk** assessment, including in those with HF⁹

ASCVD, atherosclerotic cardiovascular disease; CKD, chronic kidney disease; CV, cardiovascular; CVD, cardiovascular disease; HF, heart failure;

hsCRP, high-sensitivity C-reactive protein

1. Navar AM et al. *Atherosclerosis* 2026;419:120816; 2. Lam CSP et al. *Eur J Heart Fail* 2026;doi: 10.1093/eurjhf/xaag155 (online ahead of print); 3. Kurt B et al. *Eur Heart J* 2026;47:1799-1810; 4. Ridker PM et al. *Lancet* 2023;401:1293-1301; 5. Ridker PM et al. *Circulation* 2024;149:28-35; 6. Bay B et al. *Eur Heart J* 2025;46:3167-3177; 7. Burger PM et al. *J Am Coll Cardiol* 2023;82:414-426; 8. Ferreira JP et al. *Int J Cardiol* 2024;402:131818; 9. Mensah GA et al. *J Am Col Cardiol* 2026;87:1381-1404